Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Aurélien Marabelle, … , Victor Tse, Ronald Levy
Aurélien Marabelle, … , Victor Tse, Ronald Levy
Published May 24, 2013
Citation Information: J Clin Invest. 2013;123(6):2447-2463. https://doi.org/10.1172/JCI64859.
View: Text | PDF | Erratum
Research Article Article has an altmetric score of 52

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

  • Text
  • PDF
Abstract

Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti–CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.

Authors

Aurélien Marabelle, Holbrook Kohrt, Idit Sagiv-Barfi, Bahareh Ajami, Robert C. Axtell, Gang Zhou, Ranjani Rajapaksa, Michael R. Green, James Torchia, Joshua Brody, Richard Luong, Michael D. Rosenblum, Lawrence Steinman, Hyam I. Levitsky, Victor Tse, Ronald Levy

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2009 Total
Citations: 3 7 9 14 20 17 21 21 22 18 24 19 11 1 207
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (207)

Title and authors Publication Year
Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade
Arias-Badia M, Pai CC, Lwin YM, Chen P, Srinath A, Tanaka M, Musser E, Goodearl A, Gorman JV, Ritacco W, Fong L
Journal for Immunotherapy of Cancer 2025
Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families.
Liu R, Jiang X, Dong R, Zhang Y, Gai C, Wei P
Frontiers in immunology 2025
HVJ-E links Apolipoprotein d to antitumor effects
Ishibashi A, Ohta N, Uegaki Y, Suzuki H, Fukino K, Hisatomi Y, Tanemura A, Ohashi R, Kitamura K, Saga K, Yoshimura Y, Inubushi S, Ishida K, Ino Y, Kimura Y, Sawada K, Kimura T, Kiyohara E, Yusa K, Takahashi H, Kaneda Y, Nimura K
Journal for Immunotherapy of Cancer 2025
Targeting Innate Immunity in Glioma Therapy.
Gillard AG, Shin DH, Hampton LA, Lopez-Rivas A, Parthasarathy A, Fueyo J, Gomez-Manzano C
International journal of molecular sciences 2024
Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments
Abraham MJ, Goncalves C, McCallum P, Gupta V, Preston SE, Huang F, Chou H, Gagnon N, Johnson NA, Miller WH, Mann KK, del Rincon SV
Cell & Bioscience 2024
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A
Journal for ImmunoTherapy of Cancer 2024
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.
Nan Y, Bai Y, Hu X, Zhou K, Wu T, Zhu A, Li M, Dou Z, Cao Z, Zhang X, Xu S, Zhang Y, Lin J, Zeng X, Fan J, Zhang X, Wang X, Ju D
Journal for immunotherapy of cancer 2024
Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.
Cole M, Anastasiou P, Lee C, Yu X, de Castro A, Roelink J, Moore C, Mugarza E, Jones M, Valand K, Rana S, Colliver E, Angelova M, Enfield KSS, Magness A, Mullokandov A, Kelly G, de Gruijl TD, Molina-Arcas M, Swanton C, Downward J, van Maldegem F
Science advances 2024
Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology
Martineau R, Susini S, Marabelle A
Immunological Reviews 2024
Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities
Ganina A, Askarov M, Kozina L, Karimova M, Shayakhmetov Y, Mukhamedzhanova P, Brimova A, Berikbol D, Chuvakova E, Zaripova L, Baigenzhin A
Advances in Respiratory Medicine 2024
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist.
Pieper AA, Spiegelman DV, Felder MAR, Feils AS, Tsarovsky NW, Zaborek J, Morris ZS, Erbe AK, Rakhmilevich AL, Sondel PM
Cancer Immunology, Immunotherapy 2023
The progress of microenvironment-targeted therapies in brain metastases
Long L, Yi Z, Zeng Y, Liu Z
Frontiers in Molecular Biosciences 2023
Immunomodulatory effect of locoregional therapy in the tumor microenvironment
Xie L, Meng Z
Molecular Therapy 2023
OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs.
Yang N, Wang Y, Liu S, Tariq SB, Luna JM, Mazo G, Tan A, Zhang T, Wang J, Yan W, Choi J, Rossi A, Xiang JZ, Rice CM, Merghoub T, Wolchok JD, Deng L
Journal of Experimental Medicine 2023
BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy
Liang S, Zheng D, Liu X, Mei X, Zhou C, Xiao C, Qin C, Yue H, Lin J, Liu C, Li S, Yu JC
Frontiers in Oncology 2023
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Kiaie SH, Salehi-Shadkami H, Sanaei MJ, Azizi M, Shokrollahi Barough M, Nasr MS, Sheibani M
Journal of nanobiotechnology 2023
Challenges and opportunities in the development of combination immunotherapy with OX40 agonists
Redmond WL
Expert Opinion on Biological Therapy 2023
Sending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment
Ramirez F, Zambrano A, Hennis R, Holland N, Lakshmanaswamy R, Chacon J
Human vaccines 2023
Immune checkpoints are predominantly co-expressed by clonally expanded CD4(+)FoxP3(+) intratumoral T-cells in primary human cancers.
Bredel D, Tihic E, Mouraud S, Danlos FX, Susini S, Aglave M, Alfaro A, Mohamed-Djalim C, Rouanne M, Halse H, Bigorgne A, Tselikas L, Dalle S, Hartl DM, Baudin E, Guettier C, Vibert E, Rosmorduc O, Robert C, Ferlicot S, Parier B, Albiges L, de Montpreville VT, Besse B, Mercier O, Even C, Breuskin I, Classe M, Radulescu C, Lebret T, Pautier P, Gouy S, Scoazec JY, Zitvogel L, Marabelle A, Bonvalet M
Journal of experimental & clinical cancer research : CR 2023
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8 + T cell immunity to reject ‘cold’ tumors
M Semmrich, J Marchand, L Fend, M Rehn, C Remy, P Holmkvist, N Silvestre, C Svensson, P Kleinpeter, J Deforges, F Junghus, K Cleary, M Bodén, L Mårtensson, J Foloppe, I Teige, E Quéméneur, B Frendéus
Journal for ImmunoTherapy of Cancer 2022
LIMK2 Is a Novel Prognostic Biomarker and Correlates With Tumor Immune Cell Infiltration in Lung Squamous Cell Carcinoma
Y Su, B Xu, Q Shen, Z Lei, W Zhang, T Hu
Frontiers in immunology 2022
Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment
Y Liu, Y Geng, B Yue, P Lo, J Huang, H Jin
Frontiers in immunology 2022
Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma
H Ma, P Feng, S Yu, Z Lu, Q Yu, J Chen
BMC Cancer 2022
Intratumoral immunotherapy relies on B and T cell collaboration
Sagiv-Barfi I, Czerwinski DK, Shree T, Lohmeyer JJ, Levy R
Science Immunology 2022
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, Berneman ZN, Beuselinck B, Bol KF, Borst J, Coosemans A, Datsi A, Fučíková J, Kinget L, Neyns B, Schreibelt G, Smits E, Sorg RV, Spisek R, Thielemans K, Tuyaerts S, De Vleeschouwer S, de Vries IJ, Xiao Y, Garg AD
OncoImmunology 2022
Effects of the combination of a monoclonal agonistic mouse anti-OX40 antibody and toll-like receptor agonists: Unmethylated CpG and LPS on an MB49 bladder cancer cell line in a mouse model
Gulyás D, Kovács G, Jankovics I, Mészáros L, Lőrincz M, Dénes B
PloS one 2022
Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma
Shi ZY, Zhang SX, Fan D, Li CH, Cheng ZH, Xue Y, Wu LX, Lu KY, Yang SY, Cheng Y, Wu ZF, Gao C, Li XF, Liu HY, Li SJ
Frontiers in immunology 2022
Non-negative matrix factorization model-based construction for molecular clustering and prognostic assessment of head and neck squamous carcinoma
Li XY, An HB, Zhang LY, Liu H, Shen YC, Yang XT
Heliyon 2022
Cancer vaccines: the next immunotherapy frontier.
Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, Brody JD
2022
Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity
Reitinger C, Ipsen-Escobedo A, Hornung C, Heger L, Dudziak D, Lux A, Nimmerjahn F
Frontiers in immunology 2022
CD36 and Its Role in Regulating the Tumor Microenvironment.
Liao X, Yan S, Li J, Jiang C, Huang S, Liu S, Zou X, Zhang G, Zou J, Liu Q
Current oncology (Toronto, Ont.) 2022
Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
Yang Y, Li H, Fotopoulou C, Cunnea P, Zhao X
Frontiers in immunology 2022
Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MC, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR
2022
Therapeutic depletion of CCR8 + tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
HV Damme, B Dombrecht, M Kiss, H Roose, E Allen, EV Overmeire, D Kancheva, L Martens, A Murgaski, PM Bardet, G Blancke, M Jans, E Bolli, MS Martins, Y Elkrim, J Dooley, L Boon, JK Schwarze, F Tacke, K Movahedi, N Vandamme, B Neyns, S Ocak, I Scheyltjens, L Vereecke, FA Nana, P Merchiers, D Laoui, JA Ginderachter
Journal for ImmunoTherapy of Cancer 2021
Sphingosine-1-phosphate Receptor-1 Agonist Averts the De Novo Generation of Autoreactive T-cells in Murine Acute Graft-versus-Host Disease
M Vollmer, P Smith, C Bucher, W Krenger, LT Jeker
2021
Tumor resident regulatory T cells
A Glasner, G Plitas
Seminars in Immunology 2021
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
N Sobhani, DR Tardiel-Cyril, A Davtyan, D Generali, R Roudi, Y Li
Cancers 2021
Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?
J Cinier, M Hubert, L Besson, AD Roio, C Rodriguez, V Lombardi, C Caux, C Ménétrier-Caux
Cancers 2021
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
I Melero, E Castanon, M Alvarez, S Champiat, A Marabelle
Nature Reviews Clinical Oncology 2021
Immune Responses against Disseminated Tumor Cells
L Peng, Y Zhang, Z Wang
Cancers 2021
Emerging strategies for treating metastasis
M Esposito, S Ganesan, Y Kang
2021
The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
Z Zhou, L Lin, Y An, M Zhan, Y Chen, M Cai, X Zhu, L Lu, K Zhu
Journal of Hepatocellular Carcinoma 2021
Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights
MF Fransen, T van Hall, F Ossendorp
International journal of molecular sciences 2021
Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma
X Sun, L Wang, H Li, C Jin, Y Yu, L Hou, X Liu, Y Yu, R Yan, F Xue
Aging 2021
Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop
F Marangoni, A Zhakyp, M Corsini, SN Geels, E Carrizosa, M Thelen, V Mani, JN Prüßmann, RD Warner, AJ Ozga, MD Pilato, S Othy, TR Mempel
Cell 2021
Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy
KM van Pul, MF Fransen, R van de Ven, TD de Gruijl
Frontiers in immunology 2021
The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure
T Zhou, J Peng, Y Hao, K Shi, K Zhou, Y Yang, C Yang, X He, X Chen, Z Qian
Bioactive Materials 2021
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection
AC Glencer, JM Wong, NM Hylton, G Krings, E McCune, HT Rothschild, TA Loveday, MD Alvarado, LJ Esserman, MJ Campbell
npj Breast Cancer 2021
In vivo NIR-II structured-illumination light-sheet microscopy
F Wang, Z Ma, Y Zhong, F Salazar, C Xu, F Ren, L Qu, AM Wu, H Dai
Proceedings of the National Academy of Sciences 2021
Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy
L Cai, X Du, C Zhang, S Yu, L Liu, J Zhao, Y Zhao, C Zhang, J Wu, B Wang, Y Chen, X Su, X Yan, W Li
Cancer Immunology, Immunotherapy 2021
Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models
AA Pieper, LM Zangl, DV Speigelman, AS Feils, A Hoefges, JC Jagodinsky, MA Felder, NW Tsarovsky, IS Arthur, RJ Brown, J Birstler, T Le, PM Carlson, AM Bates, JA Hank, AL Rakhmilevich, AK Erbe, PM Sondel, RB Patel, ZS Morris
Frontiers in immunology 2021
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
NJ Mason, N Chester, A Xiong, A Rotolo, Y Wu, S Yoshimoto, P Glassman, G Gulendran, DL Siegel
mAbs 2021
Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment
T Watanabe
Cancers 2021
Domain binding and isotype dictate the activity of anti-human OX40 antibodies
J Griffiths, K Hussain, HL Smith, T Sanders, KL Cox, M Semmrich, L Mårtensson, J Kim, T Inzhelevskaya, CA Penfold, AL Tutt, CI Mockridge, HT Chan, V English, RF French, I Teige, A Al-Shamkhani, MJ Glennie, BL Frendeus, JE Willoughby, MS Cragg
Journal for ImmunoTherapy of Cancer 2020
Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis
A Ruiz-de-Angulo, M Bilbao-Asensio, J Cronin, SJ Evans, MJ Clift, J Llop, IV Feiner, R Beadman, KZ Bascarán, JC Mareque-Rivas
iScience 2020
Modulating the Tumour Microenvironment by Intratumoural Injection of Pattern Recognition Receptor Agonists
OK Burn, KK Prasit, IF Hermans
Cancers 2020
Advances in targeted therapy for malignant lymphoma
L Wang, W Qin, YJ Huo, X Li, Q Shi, JE Rasko, A Janin, WL Zhao
Signal Transduction and Targeted Therapy 2020
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
H Wang, F Franco, YC Tsui, X Xie, MP Trefny, R Zappasodi, SR Mohmood, J Fernández-García, CH Tsai, I Schulze, F Picard, E Meylan, R Silverstein, I Goldberg, SM Fendt, JD Wolchok, T Merghoub, C Jandus, A Zippelius, PC Ho
Nature Immunology 2020
Immune‐checkpoint molecules on regulatory T‐cells as a potential therapeutic target in head and neck squamous cell cancers
S Suzuki, T Ogawa, R Sano, T Takahara, D Inukai, S Akira, H Tsuchida, K Yoshikawa, R Ueda, T Tsuzuki
Cancer Science 2020
T-cell agonists in cancer immunotherapy
Y Choi, Y Shi, CL Haymaker, A Naing, G Ciliberto, J Hajjar
Journal for ImmunoTherapy of Cancer 2020
Tumor Targeted Nanocarriers for Immunotherapy
A Baeza
Molecules (Basel, Switzerland) 2020
An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer
D Sahin, N Arenas-Ramirez, M Rath, U Karakus, M Hümbelin, M van Gogh, L Borsig, O Boyman
Nature Communications 2020
Cell surface vimentin‐positive circulating tumor cell‐based relapse prediction in a long‐term longitudinal study of postremission neuroblastoma patients
IS Batth, L Dao, A Satelli, A Mitra, S Yi, H Noh, H Li, Z Brownlee, S Zhou, J Bond, J Wang, J Gill, GS Sholler, S Li
International Journal of Cancer 2020
Development and characterization of mammary intraductal (MIND) spontaneous metastasis models for triple-negative breast cancer in syngeneic mice
XL Luo, L Lin, H Hu, FL Hu, Y Lin, ML Luo, L Wang, YQ He
Scientific Reports 2020
New pathways in immune stimulation: targeting OX40
CA Silva, F Facchinetti, B Routy, L Derosa
ESMO Open 2020
Noncationic Material Design for Nucleic Acid Delivery
Z Jiang, S Thayumanavan
2020
Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies
L Tselikas, T de Baere, T Isoardo, S Susini, KS Roux, M Polrot, J Adam, M Rouanne, L Zitvogel, L Moine, F Deschamps, A Marabelle
Journal for ImmunoTherapy of Cancer 2020
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
W Hu, G Wang, Y Wang, MJ Riese, M You
iScience 2020
Development and characterization of a novel anti-OX40 antibody for potent immune activation
Z Kuang, H Jing, Z Wu, J Wang, Y Li, H Ni, P Zhang, W Wu, M Wu, S Zhou, X Qiu, D Wu, B Prinz, H Baruah, B Chen, M Yu, J Liu
Cancer Immunology, Immunotherapy 2020
Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity
A Harui, SM McLachlan, B Rapoport, TI Zarembinski, MD Roth
Cancer Immunology, Immunotherapy 2020
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
H Harjunpää, ML Asens, C Guenther, SC Fagerholm
Frontiers in immunology 2019
TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion
N Sharma, J Vacher, JP Allison
Proceedings of the National Academy of Sciences 2019
Harnessing innate immunity in cancer therapy
O Demaria, S Cornen, M Daëron, Y Morel, R Medzhitov, E Vivier
Nature 2019
A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system
A Burlion, RN Ramos, P KC, K Sendeyo, A Corneau, C Ménétrier-Caux, E Piaggio, D Olive, C Caux, G Marodon
OncoImmunology 2019
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity
MW LaFleur, TH Nguyen, MA Coxe, BC Miller, KB Yates, JE Gillis, DR Sen, EF Gaudiano, RA Abosy, GJ Freeman, WN Haining, AH Sharpe
Nature Immunology 2019
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
I Teige, L Mårtensson, BL Frendéus
Frontiers in immunology 2019
Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
K Narumi, R Miyakawa, C Shibasaki, M Henmi, Y Mizoguchi, R Ueda, H Hashimoto, N Hiraoka, T Yoshida, K Aoki
Scientific Reports 2019
Local Delivery of Ox40l , Cd80 , and Cd86 mRNA Kindles Global Anticancer Immunity
OA Haabeth, TR Blake, CJ McKinlay, AA Tveita, A Sallets, RM Waymouth, PA Wender, R Levy
Cancer research 2019
Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3 + Regulatory T Cells (Tregs) in Human Cancers—Response
A Sharma, SK Subudhi, J Blando, L Vence, J Wargo, JP Allison, A Ribas, P Sharma
Clinical cancer research 2019
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Y He, X Zhang, K Jia, R Dziadziuszko, S Zhao, J Deng, H Wang, FR Hirsch, C Zhou
Translational Lung Cancer Research 2019
Foxp3 Post-translational Modifications and Treg Suppressive Activity
G Deng, X Song, S Fujimoto, CA Piccirillo, Y Nagai, MI Greene
Frontiers in immunology 2019
Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum?
D Zamarin
Molecular Therapy 2019
TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
MJ Reilley, B Morrow, CR Ager, A Liu, DS Hong, MA Curran
Journal for ImmunoTherapy of Cancer 2019
Improving cancer immunotherapy through nanotechnology
MS Goldberg
Nature Reviews Cancer 2019
Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
O Kepp, A Marabelle, L Zitvogel, G Kroemer
Nature Reviews Clinical Oncology 2019
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
KA Autio, V Boni, RW Humphrey, A Naing
Clinical cancer research 2019
Predictive significance of T cell subset changes during ex�vivo generation of adoptive cellular therapy products for the treatment of advanced non‑small cell lung cancer
L Huang, G Qiao, M Morse, X Wang, X Zhou, J Wu, A Hobeika, J Ren, H Lyerly
Oncology Letters 2019
IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development
A Li, RH Herbst, D Canner, JM Schenkel, OC Smith, JY Kim, M Hillman, A Bhutkar, MS Cuoco, CG Rappazzo, P Rogers, C Dang, L Jerby-Arnon, O Rozenblatt-Rosen, L Cong, M Birnbaum, A Regev, T Jacks
Cell Reports 2019
Cell-mediated immune resistance in cancer
Y Wang, E Hays, M Rama, B Bonavida
2019
Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors
Agrawal S, Kandimalla ER
2019
The Future of Mesothelioma Research: Basic Science Research
Fear VS, Cook AM, Fisher SA
2019
Blocking IFNRA1 inhibits multiple myeloma-driven Treg expansion and immunosuppression
Yawara Kawano, Oksana Zavidij, Jihye Park, Michele Moschetta, Katsutoshi Kokubun, Tarek H. Mouhieddine, Salomon Manier, Yuji Mishima, Naoka Murakami, Mark Bustoros, Romanos Sklavenitis Pistofidis, Mairead Reidy, Yu J Shen, Mahshid Rahmat, Pavlo Lukyanchykov, Esilida Sula Karreci, Shokichi Tsukamoto, Jiantao Shi, Satoshi Takagi, Daisy Huynh, Antonio Sacco, Yu-Tzu Tai, Marta Chesi, P Leif Bergsagel, Aldo Roccaro, Jamil Azzi, Irene Ghobrial
Journal of Clinical Investigation 2018
Imaging activated T cells predicts response to cancer vaccines
Israt Alam, Aaron Mayer, Idit sagiv-barfi, Kezheng Wang, Ophir Vermesh, Debra Czerwinski, Emily Johnson, Michelle L. James, Ronald Levy, Sanjiv Gambhir
Journal of Clinical Investigation 2018
Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation
M Chavez, MT Silvestrini, ES Ingham, BZ Fite, LM Mahakian, SM Tam, A Ilovitsh, AM Monjazeb, WJ Murphy, NE Hubbard, RR Davis, CG Tepper, AD Borowsky, KW Ferrara
Theranostics 2018
A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity
P Kumar, P Bhattacharya, BS Prabhakar
Journal of Autoimmunity 2018
Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
C Ma, M Han, B Heinrich, Q Fu, Q Zhang, M Sandhu, D Agdashian, M Terabe, JA Berzofsky, V Fako, T Ritz, T Longerich, CM Theriot, JA McCulloch, S Roy, W Yuan, V Thovarai, SK Sen, M Ruchirawat, F Korangy, XW Wang, G Trinchieri, TF Greten
Science 2018
Effects of tumor metabolic microenvironment on regulatory T cells
Y Wang, XL Li, YZ Mo, CM Fan, L Tang, F Xiong, C Guo, B Xiang, M Zhou, J Ma, , X Wu, Y Li, GY Li, Z Zeng, W Xiong
Molecular Cancer 2018
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking
AH Turaj, KL Cox, CA Penfold, RR French, CI Mockridge, JE Willoughby, AL Tutt, J Griffiths, PW Johnson, MJ Glennie, R Levy, MS Cragg, SH Lim
Scientific Reports 2018
Using immunotherapy to boost the abscopal effect
W Ngwa, OC Irabor, JD Schoenfeld, J Hesser, S Demaria, SC Formenti
Nature Reviews Cancer 2018
Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice
A Francian, S Namen, M Stanley, K Mann, H Martinson, M Kullberg
Nanomedicine : nanotechnology, biology, and medicine 2018
Eradication of spontaneous malignancy by local immunotherapy
I Sagiv-Barfi, DK Czerwinski, S Levy, IS Alam, AT Mayer, SS Gambhir, R Levy
Science Translational Medicine 2018
CD8 + T-Cell Density Imaging with 64 Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols
JW Seo, R Tavaré, LM Mahakian, MT Silvestrini, S Tam, ES Ingham, FB Salazar, AD Borowsky, AM Wu, KW Ferrara
Clinical cancer research 2018
Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy
J Pol, G Kroemer
Cell Research 2018
mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice
OA Haabeth, TR Blake, CJ McKinlay, RM Waymouth, PA Wender, R Levy
Proceedings of the National Academy of Sciences 2018
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
RB Gombos, A Gonzalez, M Manrique, D Chand, D Savitsky, B Morin, E Breous-Nystrom, C Dupont, RA Ward, C Mundt, B Duckless, H Tang, MA Findeis, A Schuster, JD Waight, D Underwood, C Clarke, G Ritter, T Merghoub, D Schaer, JD Wolchok, M van Dijk, JS Buell, JM Cuillerot, R Stein, EE Drouin, NS Wilson, SV Pizzo
PloS one 2018
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
YT Tai, L Lin, L Xing, SF Cho, T Yu, C Acharya, K Wen, PA Hsieh, J Dulos, A van Elsas, N Munshi, P Richardson, KC Anderson
Leukemia 2018
B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors
X Zhao, Z Zhang, D Moreira, YL Su, H Won, T Adamus, Z Dong, Y Liang, HH Yin, P Swiderski, RK Pillai, L Kwak, S Forman, M Kortylewski
Molecular Therapy 2018
Combination immune checkpoint blockade as an effective therapy for mesothelioma
VS Fear, C Tilsed, J Chee, CA Forbes, T Casey, JN Solin, SM Lansley, WJ Lesterhuis, IM Dick, AK Nowak, BW Robinson, RA Lake, SA Fisher
OncoImmunology 2018
Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide
MC Merlano, AM Merlotti, L Licitra, N Denaro, E Fea, D Galizia, MD Maio, C Fruttero, P Curcio, S Vecchio, EG Russi, R Corvò
Clinical and Translational Radiation Oncology 2018
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
MJ Frank, PM Reagan, NL Bartlett, LI Gordon, JW Friedberg, DK Czerwinski, SR Long, RT Hoppe, R Janssen, AF Candia, RL Coffman, R Levy
Cancer Discovery 2018
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity
DA Knorr, R Dahan, JV Ravetch
Proceedings of the National Academy of Sciences 2018
Cancer Immunotherapy: Beyond Checkpoint Blockade
Dougan M, Dranoff G, Dougan SK
Annual Review of Cancer Biology 2018
Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols
Matthew Silvestrini, Elizabeth Ingham, Lisa Mahakian, Azadeh Kheirolomoom, Yu Liu, Brett Fite, Sarah Tam, Samantha Tucci, Katherine Watson, Andrew Wong, Arta Monjazeb, Neil Hubbard, William Murphy, Alexander Borowsky, Katherine Ferrara
JCI Insight 2017
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
DJ Messenheimer, SM Jensen, ME Afentoulis, KW Wegmann, Z Feng, DJ Friedman, MJ Gough, WJ Urba, BA Fox
Clinical cancer research 2017
Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis
L Cari, G Nocentini, G Migliorati, C Riccardi
OncoImmunology 2017
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment
A Cauwels, SV Lint, G Garcin, J Bultinck, F Paul, S Gerlo, JV der Heyden, Y Bordat, D Catteeuw, LD Cauwer, E Rogge, A Verhee, G Uzé, J Tavernier
OncoImmunology 2017
The Future of Immunotherapy: A 20-Year Perspective
DC Wraith
Frontiers in immunology 2017
Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF
AJ Manrique-Rincón, CM Beraldo, JM Toscaro, MC Bajgelman
Frontiers in immunology 2017
Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future
E Esin
BioMed Research International 2017
Delivering safer immunotherapies for cancer
L Milling, Y Zhang, DJ Irvine
Advanced Drug Delivery Reviews 2017
Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models
G Fotaki, C Jin, IK Kerzeli, M Ramachandran, MM Martikainen, A Karlsson-Parra, D Yu, M Essand
OncoImmunology 2017
TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines
TN Bullock
Current Opinion in Immunology 2017
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
F Carbonnel, E Soularue, C Coutzac, N Chaput, C Mateus, P Lepage, C Robert
Seminars in Immunopathology 2017
Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis
D Tsoneva, B Minev, A Frentzen, Q Zhang, AK Wege, AA Szalay
Molecular Therapy - Oncolytics 2017
Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells
ML Grant, N Shields, S Neumann, K Kramer, A Bonato, C Jackson, MA Baird, SL Young
IBMS BoneKEy 2017
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
JP Hebb, AR Mosley, F Vences-Catalán, N Rajasekaran, A Rosén, P Ellmark, DW Felsher
Cancer Immunology, Immunotherapy 2017
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
CR Ager, MJ Reilley, C Nicholas, T Bartkowiak, AR Jaiswal, MA Curran
Cancer immunology research 2017
Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses
DS Oh, H Kim, JE Oh, HE Jung, YS Lee, JH Park, HK Lee
Oncotarget 2017
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
X Feng, L Zhang, C Acharya, G An, K Wen, L Qiu, NC Munshi, YT Tai, KC Anderson
Clinical cancer research 2017
Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model
AL Rakhmilevich, M Felder, L Lever, J Slowinski, K Rasmussen, A Hoefges, TJ van de Voort, H Loibner, AJ Korman, SD Gillies, PM Sondel
Journal of immunology (Baltimore, Md. : 1950) 2017
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain
M Singh, C Vianden, MJ Cantwell, Z Dai, Z Xiao, M Sharma, H Khong, AR Jaiswal, F Faak, Y Hailemichael, LM Janssen, U Bharadwaj, MA Curran, A Diab, RL Bassett, DJ Tweardy, P Hwu, WW Overwijk
Nature Communications 2017
STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC
Q Han, Y Wang, M Pang, J Zhang
Journal of Experimental & Clinical Cancer Research 2017
Advances in immunotherapeutic research for glioma therapy
JT Miyauchi, SE Tsirka
Journal of Neurology 2017
Prophylactic DNA vaccine targeting Foxp3(+) regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model.
Namdar A, Mirzaei R, Memarnejadian A, Boghosian R, Samadi M, Mirzaei HR, Farajifard H, Zavar M, Azadmanesh K, Elahi S, Noorbakhsh F, Rezaei A, Hadjati J
Cancer Immunology, Immunotherapy 2017
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small cell lung cancer
Kipp Weiskopf, Nadine Jahchan, peter Schnorr, Sandra Cristea, Aaron Ring, Roy Maute, Anne Volkmer, Jens-Peter Volkmer, Jie Liu, Jing Shan Lim, Dian Yang, Garrett Seitz, Thuyen Nguyen, Di Wu, Kevin Jude, Heather Guerston, Amira Barkal, Francesca Trapani, Julie George, John Poirier, Eric Gardner, Linde Miles, Elisa de Stanchina, Shane Lofgren, Hannes Vogel, monte winslow, Caroline Dive, Roman Thomas, Charles Rudin, Matt van de Rijn, Ravindra Majeti, K. Christopher Garcia, Irving L. Weissman, Julien Sage
Journal of Clinical Investigation 2016
Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies
AM Monjazeb, MS Kent, SK Grossenbacher, C Mall, AE Zamora, A Mirsoian, M Chen, A Kol, SL Shiao, A Reddy, JR Perks, WT Culp, EE Sparger, RJ Canter, GD Sckisel, WJ Murphy
Clinical cancer research 2016
CTLA-4 limits anti-CD20-mediated tumor regression
Z Ren, J Guo, J Liao, Y Luan, Z Liu, Z Sun, X Liu, Y Liang, H Peng, YX Fu
Clinical cancer research 2016
Understanding Immune Cells in Tertiary Lymphoid Organ Development: It Is All Starting to Come Together
GW Jones, DG Hill, SA Jones
Frontiers in immunology 2016
Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma
JP Catani, RF Medrano, A Hunger, PD Valle, S Adjemian, DB Zanatta, G Kroemer, E Costanzi-Strauss, BE Strauss
Translational oncology 2016
Combinatorial approach to cancer immunotherapy: strength in numbers
AE Vilgelm, DB Johnson, A Richmond
Journal of leukocyte biology 2016
Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia
Q Zhang, DM Hossain, P Duttagupta, D Moreira, X Zhao, H Won, R Buettner, S Nechaev, M Majka, B Zhang, Q Cai, P Swiderski, YH Kuo, S Forman, G Marcucci, M Kortylewski
Blood 2016
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop
R Houot, P Gaulard, R Schreiber, I Mellman, O Lambotte, PG Coulie, T Fest, A Korman, R Levy, M Shipp, K Tarte, H Kohrt, A Marabelle, S Ansell, H Watier, A Elsas, A Balakumaran, FA Vargas, SA Quezada, G Salles, D Olive
OncoImmunology 2016
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
JM Ryan, JS Wasser, AJ Adler, AT Vella
Expert Opinion on Biological Therapy 2016
TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo
J Wu, S Li, Y Yang, S Zhu, M Zhang, Y Qiao, YJ Liu, J Chen
Oncotarget 2016
The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade
T Yamazaki, JM Pitt, M Vétizou, A Marabelle, C Flores, Ø Rekdal, G Kroemer, L Zitvogel
Cell Death and Differentiation 2016
Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody
C Wang, W Sun, G Wright, AZ Wang, Z Gu
Advanced Materials 2016
Strategies for designing synthetic immune agonists
TY Wu
Immunology 2016
Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models
JK Jang, LA Khawli, DC Canter, P Hu, TH Zhu, BW Wu, TE Angell, Z Li, AL Epstein
Cancer Immunology, Immunotherapy 2016
OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential
C Lai, S August, A Albibas, R Behar, SY Cho, ME Polak, J Theaker, AS MacLeod, RR French, MJ Glennie, A Al-Shamkhani, E Healy
Clinical cancer research 2016
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
M De Simone, A Arrigoni, G Rossetti, P Gruarin, V Ranzani, C Politano, RJ Bonnal, E Provasi, ML Sarnicola, I Panzeri, M Moro, M Crosti, S Mazzara, V Vaira, S Bosari, A Palleschi, L Santambrogio, G Bovo, N Zucchini, M Totis, L Gianotti, G Cesana, RA Perego, N Maroni, AP Ceretti, E Opocher, R De Francesco, J Geginat, HG Stunnenberg, S Abrignani, M Pagani
Immunity 2016
Nutrients and the microenvironment to feed a T cell army
MO Johnson, PJ Siska, DC Contreras, JC Rathmell
Seminars in Immunology 2016
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
P Ellmark, SM Mangsbo, C Furebring, P Norlén, TH Tötterman
Cancer Immunology, Immunotherapy 2016
Ubiquitin-dependent regulation of Foxp3 and Treg function
J Barbi, DM Pardoll, F Pan
Immunological Reviews 2015
Combination cancer immunotherapies tailored to the tumour microenvironment
MJ Smyth, SF Ngiow, A Ribas, MW Teng
Nature Reviews Clinical Oncology 2015
Cancer Immunotherapy: Strategies for Personalization and Combinatorial Approaches
V Sathyanarayanan, SS Neelapu
Molecular Oncology 2015
Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis
KS Rosenthal, K Mikecz, HL Steiner, TT Glant, A Finnegan, RE Carambula, DH Zimmerman
Expert Review of Vaccines 2015
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
A Yonezawa, S Dutt, C Chester, J Kim, HE Kohrt
Clinical cancer research 2015
Big opportunities for small molecules in immuno-oncology
JL Adams, J Smothers, R Srinivasan, A Hoos
Nature Reviews Drug Discovery 2015
In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf
L Hammerich, A Binder, JD Brody
Molecular Oncology 2015
In-Situ tumor vaccination: Bringing the fight to the tumor
RH Pierce, JS Campbell, SI Pai, JD Brody, HE Kohrt
Human Vaccines & Immunotherapeutics 2015
Engineering New Approaches to Cancer Vaccines
NK Mehta, KD Moynihan, DJ Irvine
Cancer immunology research 2015
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
SN Linch, MJ McNamara, WL Redmond
Frontiers in Oncology 2015
Targeting the tumor niche to treat cancer: Fig. 1
SS Neelapu, P Sharma
Proceedings of the National Academy of Sciences 2015
Intratumoral immunotherapy for melanoma
M Singh, WW Overwijk
Cancer Immunology, Immunotherapy 2015
Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine
K Sato, T Nakajima, PL Choyke, H Kobayashi
RSC Advances 2015
Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
M Crittenden, H Kohrt, R Levy, J Jones, K Camphausen, A Dicker, S Demaria, S Formenti
Seminars in radiation oncology 2015
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma
I Sagiv-Barfi, HE Kohrt, L Burckhardt, DK Czerwinski, R Levy
Blood 2015
Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy
H Kumon, K Sasaki, Y Ariyoshi, S Ebara, T Hiraki, S Kanazawa, M Watanabe, Y Nasu, T Sadahira, H Yanai
Clinical Medicine Insights. Oncology 2015
Porous Silicon Microparticle Potentiates Anti-Tumor Immunity by Enhancing Cross-Presentation and Inducing Type I Interferon Response
X Xia, J Mai, R Xu, JE Perez, ML Guevara, Q Shen, C Mu, HY Tung, DB Corry, SE Evans, X Liu, M Ferrari, Z Zhang, XC Li, R Wang, H Shen
Cell Reports 2015
6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice
L Jeanbart, IC Kourtis, AJ van der Vlies, MA Swartz, JA Hubbell
Cancer Immunology, Immunotherapy 2015
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
A Buqué, N Bloy, F Aranda, F Castoldi, A Eggermont, I Cremer, WH Fridman, J Fucikova, J Galon, A Marabelle, R Spisek, E Tartour, L Zitvogel, G Kroemer, L Galluzzi
OncoImmunology 2015
“ In situ ” vaccination for systemic effects in follicular lymphoma
A Kolstad, J Olweus
OncoImmunology 2015
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses
NS Joshi, EH Akama-Garren, Y Lu, DY Lee, GP Chang, A Li, M DuPage, T Tammela, NR Kerper, AF Farago, R Robbins, DM Crowley, RT Bronson, T Jacks
Immunity 2015
Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma: Neutrophils and lymphocytes: prognostic value in HNSCC
S Rachidi, K Wallace, JM Wrangle, TA Day, AJ Alberg, Z Li
Head & Neck 2015
A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts
M Chen, R Xiang, Y Wen, G Xu, C Wang, S Luo, T Yin, X Wei, B Shao, N Liu, F Guo, M Li, S Zhang, M Li, K Ren, Y Wang, Y Wei
Scientific Reports 2015
Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination
GL Hansen, G Gaudernack, PF Brunsvig, M Cvancarova, JA Kyte
Cancer Immunology, Immunotherapy 2015
Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression
LC Bailey-Downs, JE Thorpe, BC Disch, A Bastian, PJ Hauser, T Farasyn, WL Berry, RE Hurst, MA Ihnat, A Angelucci
PloS one 2014
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
D Zamarin, JD Wolchok
Molecular Therapy — Oncolytics 2014
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
D Zamarin, RB Holmgaard, SK Subudhi, JS Park, M Mansour, P Palese, T Merghoub, JD Wolchok, JP Allison
Science Translational Medicine 2014
The "Trojan Horse" Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment
D Nelson, S Fisher, B Robinson
Journal of Immunology Research 2014
Intratumoral Immunization: A New Paradigm for Cancer Therapy
A Marabelle, H Kohrt, C Caux, R Levy
Clinical cancer research 2014
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
JR Westin, F Chu, M Zhang, LE Fayad, LW Kwak, N Fowler, J Romaguera, F Hagemeister, M Fanale, F Samaniego, L Feng, V Baladandayuthapani, Z Wang, W Ma, Y Gao, M Wallace, LM Vence, L Radvanyi, T Muzzafar, R Rotem-Yehudar, RE Davis, SS Neelapu
The Lancet Oncology 2014
A brief personal history of cancer immunotherapy at Stanford: if these walls could talk…
R Levy
Immunologic Research 2014
Intraperitoneal prophylaxis with CpG oligodeoxynucleotides protects neutropenic mice against intracerebral Escherichia coli K1 infection
S Ribes, T Meister, M Ott, S Redlich, H Janova, UK Hanisch, S Nessler, R Nau
Journal of Neuroinflammation 2014
New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
D Mittal, MM Gubin, RD Schreiber, MJ Smyth
Current Opinion in Immunology 2014
Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs
L Alabanza, S Gnjatic, N Bhardwaj, J Brody
OncoImmunology 2014
Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
SN Linch, WL Redmond
OncoImmunology 2014
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
OA Haabeth, AA Tveita, M Fauskanger, F Schjesvold, KB Lorvik, PO Hofgaard, H Omholt, LA Munthe, Z Dembic, A Corthay, B Bogen
Frontiers in immunology 2014
New insights into the mechanism of action of immune checkpoint antibodies
A Marabelle, H Kohrt, R Levy
OncoImmunology 2014
Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better
RS Dronca, H Dong
Clinical cancer research 2014
The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40
A Khong, AL Cleaver, MF Alatas, BC Wylie, T Connor, SA Fisher, S Broomfield, WJ Lesterhuis, AJ Currie, RA Lake, BW Robinson
BMC Cancer 2014
CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1
P Yin, X Liu, AS Mansfield, SM Harrington, Y Li, Y Yan, H Dong
Oncotarget 2014
The early history of Stanford Immunology
PP Jones, LA Herzenberg
Immunologic Research 2014
Targeting the tumor microenvironment to enhance antitumor immune responses
Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K
Oncotarget 2014
Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity.
Alteber Z, Azulay M, Cafri G, Vadai E, Tzehoval E, Eisenbach L
Cancer Immunology, Immunotherapy 2014
Targeting Immunosuppression for cancer therapy
Cristina Ghirelli, Thorsten Hagemann
Journal of Clinical Investigation 2013
Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy
C Devaud, JA Westwood, LB John, JK Flynn, S Paquet-Fifield, CP Duong, CS Yong, HJ Pegram, SA Stacker, MG Achen, TJ Stewart, LA Snyder, MW Teng, MJ Smyth, PK Darcy, MH Kershaw
Molecular Therapy 2013
T cell responses: naive to memory and everything in between
ND Pennock, JT White, EW Cross, EE Cheney, BA Tamburini, RM Kedl
AJP Advances in Physiology Education 2013
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu
A Kunert, T Straetemans, C Govers, C Lamers, R Mathijssen, S Sleijfer, R Debets
Frontiers in immunology 2013
Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity
C Perez-Shibayama, C Gil-Cruz, M Nussbacher, E Allgäuer, L Cervantes-Barragan, R Züst, B Ludewig
PloS one 2013
Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients
F Buchegger, SM Larson, JP Mach, Y Chalandon, PY Dietrich, A Cairoli, JO Prior, P Romero, DE Speiser
Clinical & developmental immunology 2013
Local immunomodulation for cancer therapy
MF Fransen, F Ossendorp, R Arens, CJ Melief
OncoImmunology 2013
Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
A Marabelle, H Kohrt, R Levy
Clinical cancer research 2013
Cracking the combination
Y Bordon
Nature Reviews Drug Discovery 2013
Cracking the combination
Y Bordon
Nature Reviews Immunology 2013
Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer.
Mauri G, Chiodoni C, Parenza M, Arioli I, Tripodo C, Colombo MP
Cancer Immunology, Immunotherapy 2013
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 … 7 8 9 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 3 news outlets
Blogged by 2
Posted by 8 X users
Referenced in 74 patents
On 1 Facebook pages
Referenced in 1 Wikipedia pages
386 readers on Mendeley
See more details